As of January 15, 2025, third line (3L) data showed median overall survival (OS) of 16.9 months for the 22 NSCLC patients who received at least one dose of THIO (the intent-to-treat population ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback